PeptideDB

Vecuronium bromide

CAS: 50700-72-6 F: C34H57BrN2O4 W: 637.73

Vecuronium (ORG NC 45) bromide is a non-depolarizing neuromuscular blocking agent that also acts as a nicotinic acetylch
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Vecuronium (ORG NC 45) bromide is a non-depolarizing neuromuscular blocking agent that also acts as a nicotinic acetylcholine receptor (nAChR) inhibitor, a muscle relaxant, and can be used for pre-surgical anesthesia[1][2].
Invitro Vecuronium bromide (0-100 μM, 15 min) inhibits [3H] norepinephrine (NE) uptake to 65% at 100 μM in adrenal medullary cells[1].Vecuronium bromide (0-15 μM,72 hours) inhibits cancer cell proliferation and migration in a concentration-dependent manner[2].Vecuronium bromide (0-15 μM,72 hours) can significantly reduce cell viability by combining with cisplatin[2]. Cell Proliferation Assay[2] Cell Line:
In Vivo Vecuronium bromide (Intravenous injection, 0-5 μM, every 30 min, 2 hours) attenuates the response of carotid sinus nerve activity (CSNA) to hypoxia in a dose-dependent manner and inhibits the neural response of the carotid body to acetylcholine (ACh) in Wister rats[3]. Animal Model:
Name Vecuronium bromide
CAS 50700-72-6
Formula C34H57BrN2O4
Molar Mass 637.73
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Reference [1]. K Uryu, et al. Inhibition by neuromuscular blocking drugs of norepinephrine transporter in cultured bovine adrenal medullary cells. Anesth Analg. 2000 Sep;91(3):546-51. [2]. Iddrisu BabaYabasin, et al. Anticancer effects of vecuronium bromide and cisatracurium besylate on lung cancer cells (A549), in vitro. Biomedicine & Aging Pathology,Volume 4, Issue 4, [3]. Ayuko Igarashi,et al. Vecuronium directly inhibits hypoxic neurotransmission of the rat carotid body. Anesth Analg. 2002 Jan;94(1):117-22, table of contents. [4]. Meretoja, O.A., Vecuronium infusion requirements in pediatric patients during fentanyl-N2O-O2 anesthesia. Anesth Analg, 1989. 68(1): p. 20-4. [5]. Agoston, S., et al., The neuromuscular blocking action of ORG NC 45, a new pancuronium derivative, in anaesthetized patients. A pilot study. Br J Anaesth, 1980. 52 Suppl 1: p. 53S-59S. [6]. Shingu, K., et al., [Neuromuscular blocking effects of Org 9426 (rocuronium bromide); a comparative study with vecuronium bromide in Japanese patients]. Masui, 2006. 55(9): p. 1140-8.